Impact of a TDM-guided ECPA Program for Optimizing Pharmacodynamic Target Attainment of Continuous Infusion Beta-lactam-based Regimen
Trial Parameters
Brief Summary
Previous studies have clearly demonstrated a significant impact of optimised antibiotic therapy based on a TDM-guided approach in reducing the clinical and microbiological failure rate and in improving the achievement of an optimal pharmacokinetic/pharmacodynamic target. However, no study has yet evaluated this aspect in the specific scenario of liver transplant patients with documented infections with Gram-negative pathogens.
Eligibility Criteria
Inclusion Criteria: 1. adult OLT recipients (age ≥ 18 years); 2. documented Gram-negative infections occurring in the first 90 days after transplantation; 3. treatment with beta-lactam based-regimens; 4. signed informed consent. Exclusion Criteria: 1. patients receiving beta-lactam-based regimens for less than 48 hours; 2. patients with isolation of a Gram-negative resistant to all available beta-lactam classes; 3. patients on palliative care and/or not resuscitation order.